<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="94239"><DrugName>linrodostat</DrugName><DrugNamesKey><Name id="43132148">linrodostat</Name></DrugNamesKey><DrugSynonyms><Name><Value>IDO-1 inhibitors (cancer), Flexus Biosciences</Value></Name><Name><Value>cancer immunotherapy program 1, Flexus Biosciences</Value></Name><Name><Value>IDO-1 inhibitors (cancer), Bristol-Myers Squibb</Value></Name><Name><Value>FLX-B</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>IDO inhibitors (cancer), Bristol-Myers Squibb</Value></Name><Name><Value>BMS-986205</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>F-001287</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>1926517</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>IDO checkpoint inhibitor (cancer), Bristol-Myers Squibb</Value></Name><Name><Value>ONO-7701</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>IDO-1 checkpoint inhibitor (cancer), Bristol-Myers Squibb/Ono</Value></Name><Name><Value>linrodostat</Value><Types><Type>PINN</Type></Types></Name><Name><Value>1923833-60-6</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1102843">Flexus Biosciences Inc</CompanyOriginator><CompaniesPrimary><Company id="15065">Bristol-Myers Squibb Co</Company><Company id="18681">Ono Pharmaceutical Co Ltd</Company></CompaniesPrimary><CompaniesSecondary><Company id="1102843">Flexus Biosciences Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="1102843" type="Company"><TargetEntity id="5044017016" type="organizationId">Flexus Biosciences Inc</TargetEntity></SourceEntity><SourceEntity id="15065" type="Company"><TargetEntity id="4295903619" type="organizationId">Bristol-Myers Squibb Co</TargetEntity></SourceEntity><SourceEntity id="18681" type="Company"><TargetEntity id="4295877874" type="organizationId">Ono Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="1766" type="ciIndication"><TargetEntity id="10067946" type="MEDDRA"></TargetEntity><TargetEntity id="D002292" type="MeSH"></TargetEntity><TargetEntity id="-994324469" type="omicsDisease"></TargetEntity><TargetEntity id="609" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1767" type="ciIndication"><TargetEntity id="D006528" type="MeSH"></TargetEntity><TargetEntity id="88673" type="ORPHANET"></TargetEntity><TargetEntity id="-1116061312" type="omicsDisease"></TargetEntity><TargetEntity id="1973" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2054" type="ciIndication"><TargetEntity id="10066476" type="MEDDRA"></TargetEntity><TargetEntity id="D019337" type="MeSH"></TargetEntity><TargetEntity id="-105358819" type="omicsDisease"></TargetEntity><TargetEntity id="1328" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2380" type="ciIndication"><TargetEntity id="C67" type="ICD10"></TargetEntity><TargetEntity id="188.9" type="ICD9"></TargetEntity><TargetEntity id="10005003" type="MEDDRA"></TargetEntity><TargetEntity id="-2101107804" type="omicsDisease"></TargetEntity><TargetEntity id="578" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3257" type="ciIndication"><TargetEntity id="10027480" type="MEDDRA"></TargetEntity><TargetEntity id="708" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3665" type="ciIndication"><TargetEntity id="10059515" type="MEDDRA"></TargetEntity><TargetEntity id="613" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3673" type="ciIndication"><TargetEntity id="5572" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="4250" type="ciIndication"><TargetEntity id="10050513" type="MEDDRA"></TargetEntity><TargetEntity id="3229" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="725" type="ciIndication"><TargetEntity id="1164" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="C3">Phase 3 Clinical</PhaseHighest><IndicationsPrimary><Indication id="1766">Renal cell carcinoma</Indication><Indication id="1767">Hepatocellular carcinoma</Indication><Indication id="2054">Hematological neoplasm</Indication><Indication id="2380">Bladder cancer</Indication><Indication id="3257">Stage IV melanoma</Indication><Indication id="4250">Metastatic renal cell carcinoma</Indication><Indication id="651">Cancer</Indication><Indication id="725">Solid tumor</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="3665">Metastatic non small cell lung cancer</Indication><Indication id="3673">Metastatic head and neck cancer</Indication></IndicationsSecondary><ActionsPrimary><Action id="64856">Indoleamine pyrrole 2 3-dioxygenase 1 inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="7761">T-lymphocyte stimulator</Action><Action id="393">Immunostimulant</Action><Action id="1545">Anticancer</Action></ActionsSecondary><Technologies><Technology id="586">Capsule formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="1263">Immuno-oncology</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>L3</Code><Name>IMMUNOSTIMULATING AGENTS</Name></Ephmra></EphmraCodes><LastModificationDate>2019-06-25T04:29:52.000Z</LastModificationDate><ChangeDateLast>2019-06-04T00:00:00.000Z</ChangeDateLast><AddedDate>2014-12-22T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="15065" linkType="Company"&gt;Bristol-Myers Squibb&lt;/ulink&gt; (BMS), following its acquisition of &lt;ulink linkID="1102843" linkType="Company"&gt;Flexus Biosciences&lt;/ulink&gt;, and licensee &lt;ulink linkID="18681" linkType="Company"&gt;Ono Pharmaceutical&lt;/ulink&gt; are developing linrodostat (BMS-986205; ONO-7701; previously F-001287), a once-daily, indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor for the potential oral treatment of cancer, primarily bladder cancer, renal cell carcinoma and melanoma  [&lt;ulink linkID="1579650" linkType="Reference"&gt;1579650&lt;/ulink&gt;], [&lt;ulink linkID="1621561" linkType="Reference"&gt;1621561&lt;/ulink&gt;], [&lt;ulink linkID="1648763" linkType="Reference"&gt;1648763&lt;/ulink&gt;], [&lt;ulink linkID="1926517" linkType="Reference"&gt;1926517&lt;/ulink&gt;], [&lt;ulink linkID="1944779" linkType="Reference"&gt;1944779&lt;/ulink&gt;], [&lt;ulink linkID="1904994" linkType="Reference"&gt;1904994&lt;/ulink&gt;], [&lt;ulink linkID="2072298" linkType="Reference"&gt;2072298&lt;/ulink&gt;], [&lt;ulink linkID="2127587" linkType="Reference"&gt;2127587&lt;/ulink&gt;], [&lt;ulink linkID="2127420" linkType="Reference"&gt;2127420&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In November 2017, a phase III trial began for melanoma [&lt;ulink linkID="1981173" linkType="Reference"&gt;1981173&lt;/ulink&gt;]. In January 2018, the drug was listed as being in phase III  for RCC [&lt;ulink linkID="2002774" linkType="Reference"&gt;2002774&lt;/ulink&gt;], [&lt;ulink linkID="2004123" linkType="Reference"&gt;2004123&lt;/ulink&gt;]. In May 2018, a phase II trial was initiated in non-muscle-invasive bladder cancer [&lt;ulink linkID="2125070" linkType="Reference"&gt;2125070&lt;/ulink&gt;]. In October  2018, a phase III trial was initiated in muscle-invasive bladder cancer (MIBC) [&lt;ulink linkID="2072298" linkType="Reference"&gt;2072298&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Development in other cancer settings is ongoing. In January 2018, the drug was listed as  in phase II for solid tumors and hematological malignancies [&lt;ulink linkID="2002774" linkType="Reference"&gt;2002774&lt;/ulink&gt;], [&lt;ulink linkID="2004123" linkType="Reference"&gt;2004123&lt;/ulink&gt;]. In October 2018, a phase I/II trial was initiated in metastatic hepatocellular carcinoma [&lt;ulink linkID="2127587" linkType="Reference"&gt;2127587&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The drug was previously being developed in combination with &lt;ulink linkID="54804" linkType="Drug"&gt;nivolumab&lt;/ulink&gt; in head and neck  squamous cell carcinoma and non-small cell lung cancer (NSCLC). In December 2017, a phase III trial in head and neck squamous cell carcinoma was  planned; however,  in April 2018, the study was withdrawn,  due to changes in company business objectives [&lt;ulink linkID="1995647" linkType="Reference"&gt;1995647&lt;/ulink&gt;]. In November 2017, a phase III trial in NSCLC was  planned; in April 2018, the trial was initiated; however, later that month, the trial was terminated,     due to changes in company business objectives [&lt;ulink linkID="2030688" linkType="Reference"&gt;2030688&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In June 2018, BMS was developing the oral tablet formulation as an imported class 1 chemical drug in China [&lt;ulink linkID="2040779" linkType="Reference"&gt;2040779&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Bladder cancer&lt;/subtitle&gt;In October 2018, a randomized, parallel-assigned, partially blinded, phase III trial (&lt;ulink linkID="352886" linkType="Protocol"&gt;NCT03661320&lt;/ulink&gt;; CA017-078; 2017-004692-31) was initiated in the US, Europe, Israel and Brazil, to evaluate linrodostat in combination with neoadjuvant chemotherapy plus nivolumab in patients following radical cystectomy, compared with neoadjuvant chemotherapy plus  &lt;ulink linkID="54804" linkType="Drug"&gt;nivolumab&lt;/ulink&gt;  or chemotherapy alone, followed by continued maintenance therapy with nivolumab or nivolumab and BMS-986205  in patients (expected n = 1200) with MIBC.  At that time, the trial was expected to complete in December 2026   [&lt;ulink linkID="2072298" linkType="Reference"&gt;2072298&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In May 2018, a randomized, open-label, parallel-assigned, phase II study (&lt;ulink linkID="338886" linkType="Protocol"&gt;NCT03519256&lt;/ulink&gt;; CA209-9UT; 2017-003581-27; CheckMate 9UT)  was initiated in the US, Canada, China, Hong Kong, Mexico, Europe and South America to evaluate nivolumab or nivolumab plus BMS-986205 alone or combined with intravesical BCG in patients (expected n = 436) with BCG-unresponsive, high-risk, non-MIBC. The primary endpoints included proportion of carcinoma in situ (CIS) participants with complete response, duration of complete response, in CIS participants with a complete response and event free survival, for all non-CIS participants at up to 5 years. At that time, the trial was expected to complete in April 2023 [&lt;ulink linkID="2125070" linkType="Reference"&gt;2125070&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Metastatic renal cell carcinoma&lt;/subtitle&gt;In January 2018, the drug was listed as being in phase III  for RCC [&lt;ulink linkID="2002774" linkType="Reference"&gt;2002774&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2017, a randomized, open-label, parallel assigned, phase II trial (&lt;ulink linkID="282904" linkType="Protocol"&gt;NCT02996110&lt;/ulink&gt;; CA018-005; 2016-003082-26; FRACTION-RCC) was initiated in the US, Canada, Israel, Australia and Italy, in patients (expected n = 200) with  advanced RCC, to assess the safety and efficacy of &lt;ulink linkID="54804" linkType="Drug"&gt;nivolumab&lt;/ulink&gt; in combination with other therapies (nivolumab plus &lt;ulink linkID="75813" linkType="Drug"&gt;relatlimab&lt;/ulink&gt; and nivolumab plus linrodostat)  compared to  nivolumab in combination with &lt;ulink linkID="36630" linkType="Drug"&gt;ipilimumab&lt;/ulink&gt;. At that time, the trial was expected to complete in January 2022 [&lt;ulink linkID="1997391" linkType="Reference"&gt;1997391&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Melanoma&lt;/subtitle&gt;In November 2017, a randomized, double-blind, parallel assigned, phase III trial (&lt;ulink linkID="318159" linkType="Protocol"&gt;NCT03329846&lt;/ulink&gt;; CA017-055; 2017-002499-14) was planned in the US, Australia, Europe, South America, Japan and New Zealand in patients (n = 72) with previously untreated metastatic or unresectable melanoma to evaluate the efficacy of linrodostat combined with &lt;ulink linkID="54804" linkType="Drug"&gt;nivolumab&lt;/ulink&gt;, compared with nivolumab alone. At that time, the study was expected to complete in November 2022. The trial began later that month in the US and   Australia [&lt;ulink linkID="1981173" linkType="Reference"&gt;1981173&lt;/ulink&gt;]. In February 2018, the drug combination was listed as being in phase III development in the US, Europe and Japan on Ono's pipeline [&lt;ulink linkID="2004123" linkType="Reference"&gt;2004123&lt;/ulink&gt;]. In  March 2018, the trial was recruiting in Canada. In April 2018, the trial was active and no longer recruiting. In July 2018, study completion was expected in July 2020  [&lt;ulink linkID="1981173" linkType="Reference"&gt;1981173&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Solid tumor&lt;/subtitle&gt;In June 2018, an IND application of an oral tablet formulation was filed in China, presumably for solid tumor [&lt;ulink linkID="2040779" linkType="Reference"&gt;2040779&lt;/ulink&gt;]. In August 2018, review of the application was concluded though the outcome was not published yet [&lt;ulink linkID="2085842" linkType="Reference"&gt;2085842&lt;/ulink&gt;]. In January 2019, a phase I/II interventional, non-randomized, single group assignment study (&lt;ulink linkID="365400" linkType="Protocol"&gt;NCT03792750&lt;/ulink&gt;; CA017-076) to evaluate the pharmacokinetics, pharmacodynamics, safety, and tolerability of BMS-986205 alone and in combination with nivolumab in Chinese patients with advanced malignant solid tumors. At that time, the study was expected to complete in June 2020 [&lt;ulink linkID="2109377" linkType="Reference"&gt;2109377&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2018, a non-randomized, parallel assignment, open label, phase I/II trial (&lt;ulink linkID="331718" linkType="Protocol"&gt;NCT03459222&lt;/ulink&gt;; CA224-048, 2018-000058-22) was to begin in June 2018, in the US to assess the safety and anti-tumor activity of relatlimab in combination with both nivolumab and linrodostat, or in combination with both nivolumab and ipilimumab in patients (expected n =230) with advanced malignant tumors. At that time, the trial was expected to complete in May 2022 [&lt;ulink linkID="2040620" linkType="Reference"&gt;2040620&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In  April 2015, an IND was to be filed in 2H15 [&lt;ulink linkID="1648763" linkType="Reference"&gt;1648763&lt;/ulink&gt;]. In January 2016, an open-label, randomized, parallel-assigned, phase I/IIa trial (&lt;ulink linkID="251423" linkType="Protocol"&gt;NCT02658890&lt;/ulink&gt;; CA017-003; 2015-004914-79) to evaluate the safety and efficacy of linrodostat in combination with &lt;ulink linkID="54804" linkType="Drug"&gt;nivolumab&lt;/ulink&gt; in patients (expected n = 252) with advanced malignant tumors was expected to begin in February 2016 in the US, Australia, Canada, France, Germany and Spain. In February 2016, the trial was initiated. At that time, the trial was expected to complete in February 2020 [&lt;ulink linkID="1730689" linkType="Reference"&gt;1730689&lt;/ulink&gt;]. In April 2017, data from the trial were presented at the 108th AACR Annual Meeting in Washington DC. As of February 2017, the MTD had not been reached, but linrodostat plus nivolumab treatment was well tolerated, with only two patients discontinuing treatment due to DLTs. The most commonly reported treatment-related adverse events (TRAEs) were decreased appetite, fatigue, nausea, diarrhea, and vomiting. Grade 3 TRAEs were reported in three patients during the combination therapy; however, no grade 3 events were reported during linrodostat monotherapy lead-in. No grade 4 or 5 TRAEs were reported with linrodostat alone or in combination with nivolumab [&lt;ulink linkID="1914153" linkType="Reference"&gt;1914153&lt;/ulink&gt;], [&lt;ulink linkID="1915752" linkType="Reference"&gt;1915752&lt;/ulink&gt;]. In November 2017, data from the phase I/IIa trial were presented at the 32nd annual meeting of the Society for Immunotherapy of Cancer (SITC) in National Harbor, MD. Data demonstrated the primary endpoint, which was the maximum tolerated dose (MTD) was found to be 200 mg. The recommended dose for further study was determined to be 100 mg. Furthermore, in the dose expansion phase, findings for anti-tumor activity (primary endpoint) were reported in two cohorts – heavily pre-treated bladder (n=25) and cervical cancer patients (n=22). In the bladder cancer cohort, the objective response rate (ORR) and disease control rate (DCR) were 32% and 44%, respectively. In the cervical cancer cohort, the ORR was 14% and DCR was 64%. The study also measured ORR by PD-L1 expression levels; in patients who express PD-L1 ≥1%, ORR was 46% and 25% in the bladder (n=13) and cervical cancer cohorts (n=12), respectively. In patients who express PD-L1 &amp;lt;1%, ORR was 22% in the bladder cancer cohort (n=9); no response was observed in cervical cancer patients (n=7) [&lt;ulink linkID="1981237" linkType="Reference"&gt;1981237&lt;/ulink&gt;]. Additional results were presented at the same conference. Out of four patients, two reported DLTs of grade 3 AST/ALT increased, grade 2 anemia and fatigue at 400 mg. Overall, 47% of patients experienced treatment-related adverse events (11% grade 3/4) and 2% of patients discontinued owing to study drug toxicity. Safety profile reported was comparable to that previously observed for nivolumab monotherapy. In an analysis of 39 paired pre- versus on-treatment tumor samples collected from various tumor types, linrodostat + nivolumab increased the percentage of proliferating CD8+ T cells and reduced kynurenine [&lt;ulink linkID="1984300" linkType="Reference"&gt;1984300&lt;/ulink&gt;]. In June 2018, further data were presented at the 54th ASCO Annual Meeting in Chicago, IL. Complete response, partial response, stable disease, progressive disease, ORR and DCR were 11, 26, 19, 44, 37 and 56%, respectively, in all IO naive patients; 0, 38, 8, 54, 38 and 46%, respectively, in linrodostat 100 mg + nivolumab group; 21, 14, 29, 36, 36 and 64%, respectively, in linrodostat 200 mg + nivolumab group; 14, 36, 14, 36, 50 and 64%, respectively, in PD-L1 positive; and 10, 20, 20, 50, 30 and 50%, respectively, in PD-L1 negative group [&lt;ulink linkID="2039568" linkType="Reference"&gt;2039568&lt;/ulink&gt;]. In February 2019, further data were presented at the 2019 ASCO Genitourinary Cancers Symposium in San Francisco, CA. The proportion of patients reported with treatment-related adverse events [TRAEs] were presented 57% with the most common were fatigue (15%) and nausea (12%). Due to TRAEs, 19 patients discontinued and 3 died in the study [&lt;ulink linkID="2120464" linkType="Reference"&gt;2120464&lt;/ulink&gt;]. In March 2019, updated safety across all tumor cohorts as well as safety and long-term efficacy results were presented at the 2019 International EAU Meeting in Barcelona, Spain.  The proportion of patients with advanced bladder cancer in immune-oncology naive, BMS-986205 at 100 mg + nivolumab and BMS-986205 at 200 mg + nivolumab treatment groups who continued treatment was 29, 29 and 25%; who showed disease progression was 52, 64 and 50%; and study drug toxicity was 11, 7 and 13%, respectively. No deaths or withdrawals from treatment or adverse events related to study drug were reported   [&lt;ulink linkID="2128633" linkType="Reference"&gt;2128633&lt;/ulink&gt;]. In May 2019, updated safety data were presented at the 2019 AUA Annual Meeting in Chicago, IL. In the BMS-986205 + nivolumab in subgroup with baseline visceral metastases (yes versus no), ORR was 30 versus 75% and DCR was 52 versus 75%; and in subgroup with baseline liver metastases (yes versus no), ORR was 33 versus 39% and DCR was 44 and 61%, respectively [&lt;ulink linkID="2150649" linkType="Reference"&gt;2150649&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Metastatic non small cell lung cancer&lt;/subtitle&gt;In January 2018, a randomized, parallel-assignment, open-label, phase III study (&lt;ulink linkID="327600" linkType="Protocol"&gt;NCT03417037&lt;/ulink&gt;; CA017-062; 2017-003058-18) was planned to initiate in the US, Australia, Brazil,  Canada, Europe, Japan, South Korea, Mexico, Taiwan and Turkey, to evaluate linrodostat in combination with &lt;ulink linkID="54804" linkType="Drug"&gt;nivolumab&lt;/ulink&gt; with or without chemotherapy versus chemotherapy in patients (expected n = 1174) with previously untreated stage IV or recurrent NSCLC. However, in April 2018, the study was withdrawn, due to changes in company business objectives  [&lt;ulink linkID="2030688" linkType="Reference"&gt;2030688&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Metastatic head and neck cancer&lt;/subtitle&gt;In December 2017, a phase III trial in squamous cell carcinoma was  planned. In April 2018, 	the open-label, global, randomized, parallel-group, phase III trial (&lt;ulink linkID="324188" linkType="Protocol"&gt;NCT03386838&lt;/ulink&gt;; CA017-063; 2017-003059-46) was initiated in the US, Canada, Europe and Turkey in patients (expected n =  580) with first-line recurrent/metastatic squamous cell carcinoma of head and neck, to assess the safety and efficacy of nivolumab in combination with linrodostat vs standard of care EXTREME regimen. However, later that month, the trial was terminated, due to changes in company business objectives  [&lt;ulink linkID="1995647" linkType="Reference"&gt;1995647&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Hepatocellular carcinoma&lt;/subtitle&gt;In October 2018, Bristol-Myers Squibb in collaboration with National Cancer Institute initiated an open-label, phase I/II study (&lt;ulink linkID="355333" linkType="Protocol"&gt;NCT03695250&lt;/ulink&gt;) in the US to asses BMS-986205 in combination with nivolumab as first line therapy in hepatocellular carcinoma patients (expected n = 23). The primary endpoints were to determine adverse events and objective response rate. At that time, trial was expected to complete in December 2021  [&lt;ulink linkID="2127587" linkType="Reference"&gt;2127587&lt;/ulink&gt;]. In March 2019, it was reported that the estimated study duration was 36 months with a 24-month accrual period for a total of 17 patients  [&lt;ulink linkID="2127420" linkType="Reference"&gt;2127420&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I studies&lt;/subtitle&gt;In November 2017, an open-label, randomized, four-cohort, parallel group, phase I  trial (&lt;ulink linkID="320068" linkType="Protocol"&gt;NCT03346837&lt;/ulink&gt;; CA017-051) was planned to be  initiated in healthy subjects (expected n = 56), to assess the effects of &lt;ulink linkID="3411" linkType="Drug"&gt;itraconazole&lt;/ulink&gt; and rifampin on the pharmacokinetics, safety, and tolerability of linrodostat. At that time, the trial was expected to complete in December 2017  [&lt;ulink linkID="1996520" linkType="Reference"&gt;1996520&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2017, data from a phase Ia trial in healthy volunteers were presented at the Sixth ACSMEDI-EFMC Medicinal Chemistry Frontiers Symposium in Philadelphia, PA. A once-daily, 25-mg dose resulted in plasma concentrations that exceeded the IC50 values, with dose escalation to 50, 100 and 200 mg, resulting in plasma levels &amp;gt;/= the IC90 value. A whole blood ex vivo assay showed &amp;gt; 90% inhibition of IDO1 at doses of &amp;gt;/= 50 mg qd [&lt;ulink linkID="1942593" linkType="Reference"&gt;1942593&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2017, a single group assigned, phase I trial (&lt;ulink linkID="302186" linkType="Protocol"&gt;NCT03192943&lt;/ulink&gt;; CA017-048) to assess the safety and tolerability for the combination therapy of linrodostat and nivolumab in patients (expected n = 18) with advanced tumors was planned to be initiated in July 2017 in Japan. At that time, the trial was expected to complete in July 2019. Recruitment began in August 2017 [&lt;ulink linkID="1944788" linkType="Reference"&gt;1944788&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By March 2017, the program had been in phase I trials for the treatment of solid tumors and hematologic cancers in Japan [&lt;ulink linkID="1926517" linkType="Reference"&gt;1926517&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;By November 2017, a series of o-phenylenediamine derivatives had been synthesized and evaluated as IDO1 inhibitors. One of the most potent compounds inhibited IDO1 activity in HeLa cells with IC50 value of 0.004 microM [&lt;ulink linkID="2034958" linkType="Reference"&gt;2034958&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2017, preclinical data were presented at the 108th AACR Annual Meeting in Washington DC. Linrodostat inhibited kynurenine production with IC50 values of 1.7, 1.1 and &amp;gt; 2000 and 4.6, 6.3 and &amp;gt; 2000 nM in human HeLa, HEK293 expressing human IDO-1 and tryptophan-2, 3-dioxygenase cell-based assays, and rat M109, HEK293 expressing mouse ID0-1 and -2 cell-based assays, respectively. In human SKOV-3 xenografts, at doses of 5, 20 and 125 mg/kd qdx5,  the serum and tumor AUC(0 to 24h) values were 0.8, 4.2 and 23 and 3.5, 11 and 40 microM h, respectively, and area under the effect curve was 39, 32 and 41 and 60, 63 and 76% kyn, respectively [&lt;ulink linkID="1914076" linkType="Reference"&gt;1914076&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2017, preclinical data were presented at the 253rd ACS National Meeting and Exhibition in San Francisco, CA. Linrodostat showed potent and selective inhibition of IDO-1 enzyme (IC50 = 1.7nM) and potent growth inhibition in cellular assays (IC50 = 3.4 nM) in SKOV3 cells. A good pharmacokinetic profile was seen at oral and iv doses in rats, dogs and monkeys.  The compound showed good oral exposure and efficacy in in vivo assays [&lt;ulink linkID="1914735" linkType="Reference"&gt;1914735&lt;/ulink&gt;], [&lt;ulink linkID="1916155" linkType="Reference"&gt;1916155&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2015, preclinical data were presented at the 106th AACR meeting in Philadelphia, PA. Against human tryptophan-2, 3-dioxygenase and human IDO-1with IC50 values of &amp;gt; 5 and 0.002 microM, respectively. FLX-B showed potent anti-proliferative activity with EC50 value of 0.002 microM and had plasma t1/2 of 20 h. In LPS challenged mice, FLX-B significantly retarded growth ofCT26 tumors  [&lt;ulink linkID="1650191" linkType="Reference"&gt;1650191&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2014, the program was listed as being in preclinical development and a clinical candidate was expected to be selected in early 2015  [&lt;ulink linkID="1621561" linkType="Reference"&gt;1621561&lt;/ulink&gt;], [&lt;ulink linkID="1621694" linkType="Reference"&gt;1621694&lt;/ulink&gt;], [&lt;ulink linkID="1635766" linkType="Reference"&gt;1635766&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-02-02T00:00:00.000Z</StatusDate><Source id="2004123" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18681">Ono Pharmaceutical Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2380">Bladder cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-02-01T00:00:00.000Z</StatusDate><Source id="2116137" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2380">Bladder cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-10-12T00:00:00.000Z</StatusDate><Source id="2072298" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-11-21T00:00:00.000Z</StatusDate><Source id="1981173" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2380">Bladder cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-10-12T00:00:00.000Z</StatusDate><Source id="2072298" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-11-21T00:00:00.000Z</StatusDate><Source id="1981173" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1766">Renal cell carcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-01-01T00:00:00.000Z</StatusDate><Source id="2002774" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-02-02T00:00:00.000Z</StatusDate><Source id="2004123" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-03-26T00:00:00.000Z</StatusDate><Source id="1981173" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18681">Ono Pharmaceutical Co Ltd</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2380">Bladder cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-02-01T00:00:00.000Z</StatusDate><Source id="2116137" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="XE">South America</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-11-21T00:00:00.000Z</StatusDate><Source id="1981173" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="IL">Israel</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2380">Bladder cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-10-12T00:00:00.000Z</StatusDate><Source id="2072298" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2380">Bladder cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-10-12T00:00:00.000Z</StatusDate><Source id="2072298" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-11-21T00:00:00.000Z</StatusDate><Source id="1981173" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2380">Bladder cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-10-12T00:00:00.000Z</StatusDate><Source id="2072298" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="IL">Israel</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-01-17T00:00:00.000Z</StatusDate><Source id="1997391" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-01-17T00:00:00.000Z</StatusDate><Source id="1997391" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="IT">Italy</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-01-17T00:00:00.000Z</StatusDate><Source id="1997391" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2054">Hematological neoplasm</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-02-02T00:00:00.000Z</StatusDate><Source id="2004123" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-02-25T00:00:00.000Z</StatusDate><Source id="1730689" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-03-01T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2054">Hematological neoplasm</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-02-02T00:00:00.000Z</StatusDate><Source id="2004123" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="CN">China</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-02T00:00:00.000Z</StatusDate><Source id="2109377" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-02-02T00:00:00.000Z</StatusDate><Source id="2004123" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-02-02T00:00:00.000Z</StatusDate><Source id="2004123" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-01-17T00:00:00.000Z</StatusDate><Source id="1997391" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18681">Ono Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-03-31T00:00:00.000Z</StatusDate><Source id="1926517" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18681">Ono Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="2054">Hematological neoplasm</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-03-31T00:00:00.000Z</StatusDate><Source id="1926517" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-03-31T00:00:00.000Z</StatusDate><Source id="1926517" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="2054">Hematological neoplasm</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-03-31T00:00:00.000Z</StatusDate><Source id="1926517" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-04-26T00:00:00.000Z</StatusDate><Source id="2030688" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-04-26T00:00:00.000Z</StatusDate><Source id="2030688" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18681">Ono Pharmaceutical Co Ltd</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-04-26T00:00:00.000Z</StatusDate><Source id="2030688" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="TR">Turkey</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-04-26T00:00:00.000Z</StatusDate><Source id="1995647" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-04-26T00:00:00.000Z</StatusDate><Source id="1995647" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-04-26T00:00:00.000Z</StatusDate><Source id="2030688" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="TR">Turkey</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-04-26T00:00:00.000Z</StatusDate><Source id="2030688" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-04-26T00:00:00.000Z</StatusDate><Source id="2030688" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-04-26T00:00:00.000Z</StatusDate><Source id="1995647" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-04-26T00:00:00.000Z</StatusDate><Source id="2030688" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-04-26T00:00:00.000Z</StatusDate><Source id="2030688" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18681">Ono Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-04-26T00:00:00.000Z</StatusDate><Source id="2030688" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-04-26T00:00:00.000Z</StatusDate><Source id="2030688" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-04-26T00:00:00.000Z</StatusDate><Source id="1995647" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18681">Ono Pharmaceutical Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-04-26T00:00:00.000Z</StatusDate><Source id="2030688" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-04-26T00:00:00.000Z</StatusDate><Source id="2030688" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-04-26T00:00:00.000Z</StatusDate><Source id="2030688" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1102843">Flexus Biosciences Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-12-17T00:00:00.000Z</StatusDate><Source id="1621561" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-04-08T00:00:00.000Z</StatusDate><Source id="1648763" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-01-17T00:00:00.000Z</StatusDate><Source id="1997391" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-11-02T00:00:00.000Z</StatusDate><Source id="1981173" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-11-02T00:00:00.000Z</StatusDate><Source id="1981173" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-02-25T00:00:00.000Z</StatusDate><Source id="1730689" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-02-25T00:00:00.000Z</StatusDate><Source id="1730689" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-02-25T00:00:00.000Z</StatusDate><Source id="1730689" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-04-02T00:00:00.000Z</StatusDate><Source id="1995647" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-04-02T00:00:00.000Z</StatusDate><Source id="1995647" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-04-02T00:00:00.000Z</StatusDate><Source id="1995647" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="TR">Turkey</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-04-02T00:00:00.000Z</StatusDate><Source id="1995647" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-01-31T00:00:00.000Z</StatusDate><Source id="2030688" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-01-31T00:00:00.000Z</StatusDate><Source id="2030688" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-01-31T00:00:00.000Z</StatusDate><Source id="2030688" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-01-31T00:00:00.000Z</StatusDate><Source id="2030688" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-01-31T00:00:00.000Z</StatusDate><Source id="2030688" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-01-31T00:00:00.000Z</StatusDate><Source id="2030688" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-01-31T00:00:00.000Z</StatusDate><Source id="2030688" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-01-31T00:00:00.000Z</StatusDate><Source id="2030688" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-01-31T00:00:00.000Z</StatusDate><Source id="2030688" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="TR">Turkey</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-01-31T00:00:00.000Z</StatusDate><Source id="2030688" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18681">Ono Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-01-31T00:00:00.000Z</StatusDate><Source id="2030688" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18681">Ono Pharmaceutical Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-01-31T00:00:00.000Z</StatusDate><Source id="2030688" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18681">Ono Pharmaceutical Co Ltd</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-01-31T00:00:00.000Z</StatusDate><Source id="2030688" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-12-29T00:00:00.000Z</StatusDate><Source id="1995647" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-12-29T00:00:00.000Z</StatusDate><Source id="1995647" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-12-29T00:00:00.000Z</StatusDate><Source id="1995647" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="TR">Turkey</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-12-29T00:00:00.000Z</StatusDate><Source id="1995647" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-11-02T00:00:00.000Z</StatusDate><Source id="1981173" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="XE">South America</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-11-02T00:00:00.000Z</StatusDate><Source id="1981173" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-11-02T00:00:00.000Z</StatusDate><Source id="1981173" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2380">Bladder cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-09-07T00:00:00.000Z</StatusDate><Source id="2072298" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2380">Bladder cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-09-07T00:00:00.000Z</StatusDate><Source id="2072298" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2380">Bladder cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-09-07T00:00:00.000Z</StatusDate><Source id="2072298" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="IL">Israel</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2380">Bladder cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-09-07T00:00:00.000Z</StatusDate><Source id="2072298" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-06-19T00:00:00.000Z</StatusDate><Source id="2040779" type="OTHER"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-11446"><Name>Indoleamine pyrrole 2 3-dioxygenase 1</Name><SwissprotNumbers><Swissprot>P14902</Swissprot><Swissprot>P28776</Swissprot><Swissprot>Q9ERD9</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="15065">Bristol-Myers Squibb Co</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="18681">Ono Pharmaceutical Co Ltd</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>Cc1ccc(cc1)NC(=O)Nc2cc(ccc2N(CC(C)C)CC(C)C)c3ccccc3c4[nH]nnn4</Smiles><Smiles>C[C@@H](C(=O)Nc1ccc(cc1)Cl)[C@H]2CC[C@H](CC2)c3c4c(ncc3)ccc(c4)F</Smiles></StructureSmiles><Deals><Deal id="108573" title="Medarex and Ono to develop multiple immunotherapies for several types of tumors worldwide   "></Deal></Deals><PatentFamilies><PatentFamily id="2897577" number="WO-2015031295" title="IDO inhibitors"></PatentFamily><PatentFamily id="3135299" number="WO-2017118864" title="Modified oncolytic viurs"></PatentFamily><PatentFamily id="3927039" number="WO-2018017529" title="Radioligands for imaging the ido1 enzyme"></PatentFamily><PatentFamily id="4329300" number="WO-2019006283" title="Amorphous and crystalline forms of IDO inhibitors"></PatentFamily><PatentFamily id="4329304" number="WO-2019006292" title="Substituted quinolinycyclohexylpropanamide compounds and improved methods for their preparation"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="1">Analyte</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Replimune Group Inc" id="1114214"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Bristol-Myers Squibb Co" id="15065"></CompanyLink><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>